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Serological response to treatment of syphilis with orally 
administered doxycycline or intramuscularly adminis-
tered penicillin was assessed in patients with concur-
rent HIV. All HIV-infected individuals diagnosed with 
syphilis attending 3 hospitals in Copenhagen, Denmark 
were included. Odds ratios (ORs) with 95% confidence 
intervals (CI) associated with serological outcome were 
modelled using propensity-score-adjusted logistic reg-
ression analysis. In total, 202 cases were treated with 
doxycycline or intramuscular penicillin. At 12 months, 
serological failure was observed in 12 cases (15%) trea-
ted with doxycycline and in 8 cases (17%) treated with 
penicillin (OR 0.78 (95% CI 0.16–3.88), p = 0.76). The se-
rological cure rate at 12 months was highest in patients 
with primary syphilis (100%), followed by patients with 
secondary (89%), early latent (71%) and late latent 
(67%) syphilis (p = 0.006). In conclusion, this study pro-
vides evidence for the use of doxycycline as a treatment 
option when treating a HIV-infected population for sy-
philis. Key words: syphilis; HIV; penicillin; doxycycline; 
serology. 
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Since its introduction in the 1940s, penicillin has been 
used for treatment of syphilis. Penicillin G, administered 
parenterally, is the recommended first-line treatment for 
all stages of syphilis in Europe and the USA; however, 
the preparation, dosage and length of treatment depend on 
disease stage and whether there is central nervous system 
(CNS) involvement (1, 2). In the 1950s, successful use of 
tetracycline derivatives for treatment of syphilis was re-
ported (3, 4). Doxycycline, a tetracycline derivative with 
increased bioavailability and fewer side-effects, was then 
introduced. An uncontrolled observational study from 
1979 evaluated the serological response to doxycycline 
treatment of syphilis during the course of one year and 
found excellent response rates for patients with primary 
(100%), secondary and early latent syphilis (90%) (5). 
In a more recent retrospective case-control study, doxy-
cycline was compared with benzathine penicillin G in 
doses recommended by the Centers for Disease Control 
and Prevention (CDC) and appeared to be an effective 
agent for treatment of early syphilis (6). Azithromycin 
has also been used as a treatment alternative, but very 
high rates of the resistance-conferring A2058G mutation 
have been reported from Ireland, Eastern Europe, the 
USA and China (7–10), limiting its usefulness.
Syphilis and HIV co-infection is common in Denmark 
(11). Since a case report documented neurological rel-
apse after treatment with benzathine penicillin G in an 
HIV-infected individual (12), the management of sy-
philis in patients with concurrent HIV has been debated. 
Although many controversies exist on the impact of 
HIV on the clinical course of syphilis (13), serologically 
defined treatment failure has been documented to be 
more common in patients with primary and secondary 
syphilis and concurrent HIV (14). However, a recent 
study found that HIV co-infection had an impact only 
on the serological response in patients with primary 
syphilis and a CD4 cell count of < 500 cells/µl (15). 
Today many HIV-infected individuals are treated with 
combination antiretroviral therapy (cART) and may 
have a restored immune system, resulting in reduced 
rates of serological failure (16). The CDC recommends 
that HIV-infected individuals are evaluated clinically 
and serologically for treatment failure at 3, 6, 9, 12 and 
24 months after therapy (2). In general, the serological 
response after treatment with benzathine penicillin G 
is known to be affected by several factors; for example, 
the rate of decline is more rapid in patients with high-
titre seroreactivity compared with those with low-titre 
seroreactivity. Moreover, patients with a prior infection 
with syphilis have a slower reduction in titres (17). 
The aim of the present study was to compare the 
serological response to treatment of primary, secon-
dary, early or late latent syphilis with intramuscularly 
administered penicillin or orally administered doxycy-
cline in patients with concurrent HIV. Propensity score 
adjustment and matching were employed to reduce bias 
between treatment groups owing to the unequal chance 
of allocation to a treatment group (18, 19).
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METHODS
The study was performed as a retrospective study of HIV-infected 
individuals ≥ 18 years of age diagnosed with syphilis between 
1 May 2004 and 31 October 2009. All HIV-infected individuals 
attending the Department of Infectious Diseases at Copenhagen 
University Hospital, Rigshospitalet, the Department of Infectious 
Diseases at Copenhagen University Hospital, Hvidovre, and 
the sexually transmitted disease (STD) clinic at the Department 
of Dermato-venereology at Copenhagen University Hospital, 
Bispebjerg, were included. Sociodemographic information, mode 
of acquisition (e.g. men who have sex with men (MSM) status) 
and clinical data were extracted from the patient files. 
Therapy consisted of oral doxycycline or intramuscular 
penicillin. Disease stage was based on clinical examination, 
patient history and the results of serological tests. Patients were 
classified as having primary syphilis, secondary syphilis, early 
latent syphilis, late latent syphilis or tertiary syphilis. Serolo-
gical cure was defined as a ≥4-fold decline in rapid plasma 
reagin (RPR) titres following therapy. Serological failure was 
defined as a lack of a 4-fold decline. To capture all available 
serological data, we obtained the serological test results from 
Statens Serum Institut, where all serological testing of syphilis 
was centralized during the study period. The non-treponemal 
test RPR was determined by agglutination and furthermore, 3 
treponemal tests were used: anti-flagellum IgM (AF-M) was 
determined by a capture enzyme-linked immunoassay (ELISA), 
anti-flagellum IgG (AF-G) was determined by an indirect 
ELISA (20–22) and the fluorescent treponemal antibody ab-
sorption test (FTA-ABS) was done by immunofluorescence 
microscopy. For further details see Appendix S11.
RESULTS
Clinical and baseline characteristics
From 1 May 2004 to 31 October 2009, a total of 221 
cases of syphilis were diagnosed in 172 HIV-infected 
individuals attending 3 hospitals in the Copenhagen 
area of Denmark (138 individuals contributed with a 
single episode, 24 with 2 episodes, 7 with 3 episodes, 1 
with 4 episodes and 2 with 5 episodes). Characteristics 
of the individuals are shown in Table I. The patients 
were diagnosed with primary, secondary, early and 
late latent syphilis. No cases of tertiary syphilis were 
seen in these patients. Patients with neurosyphilis (14 
individuals) were excluded from the analysis of se-
rological response to treatment (Fig. 1). In total, 202 
cases were treated with doxycycline or intramuscular 
penicillin. Of these, 126 cases were evaluated at 12 
months; 78 cases were treated with doxycycline and 
48 cases were treated with penicillin. Table SI1 sum-
marizes the demographic and clinical characteristics 
of the doxycycline treatment group and the penicillin 
treatment group. No statistically significant differences 
between treatment groups were observed, except for 
CD4 cell count ≤ 200 cells/µl, which was less common 
and proportion on cART, which was higher for the 
doxycycline-treated group (Table SI1).
Serological outcome
Serological outcome was assessed at 3, 6, 9 and 12 
months following therapy and no statistically significant 
differences were observed between treatment groups at 
any time-point (all p > 0.05). At 12 months, the time-point 
often used to evaluate serological cure rates, 20 cases of 
serological failure were observed (Table II). All these 
patients had reactive treponemal tests, which confirmed 
the diagnosis of syphilis. By logistic regression analysis, 
only age (OR 1.04 (95% CI 1.00–1.09) per year incre-
ment) was associated with failure, whereas sex, syphilis 
stage, mode of acquisition or cART were not associated 
with serological outcome. In the doxycycline group, 12 
cases (15%) of serological failure were observed. In the 
penicillin group, 8 cases (17%) of serological failure 
were observed, resulting in a non-significant difference 
of 2% (95% CI –1.08–5.08%) and corresponding to an 
OR of 0.78 (95% CI 0.16–3.88, p = 0.76) after adjust-1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2289
Table I. Main characteristics of the study population: 172 HIV-
infected individuals contributed with 221 cases of syphilis
Characteristic
Individuals 
(n = 172)
Cases 
(n = 221)
Age, years, median (range) 40 (20–78) 40 (20–83)
Female, n (%) 2 (1) 2 (1)
Male, n (%) 170 (99) 219 (99)
MSM, n (%) 160 (94) 207 (95)
Danish citizen, n (%) 132 (77) 175 (80)
Syphilis stage, n (%)
  Primary 14 (8) 21 (10)
  Secondary 102 (60) 130 (59)
  Early latent 23 (13) 31 (14)
  Late latent 31 (18) 36 (16)
  Relapse 0 (0) 1 (0)
  Unknown 2 (1) 2 (1)
Neurosyphilis, n (%) 12 (7) 14 (6)
Syphilis treatment, n (%)
  Doxycycline 101 (59) 129 (59)
  Penicillin intramuscularly 58 (34) 76 (34)
  Penicillin intravenously 4 (2) 6 (3)
  Ceftriaxone 6 (3) 7 (3)
  Unknown 3 (2) 3 (1)
Infected in Denmark, n (%) 104 (60) 127 (57)
History of syphilis, n (%) 59 (34) 108 (49)
CD4 cell count, cells/µl, median (IQR) 460 (336–639) 450 (338–630)
  ≤ 200 14 (8) 17 (8)
  > 200 104 (61) 129 (58)
  Unknown 54 (31) 75 (34)
HIV RNA, log10 copies/ml, mean (SD) 2.24 (1.66) 2.18 (1.65)
HIV RNA, copies/ml, n (%)
  ≤ 200 77 (45) 99 (45)
  > 200–100,000 30 (18) 36 (16)
  ≥ 100,000 11 (6) 13 (6)
  Unknown 54 (31) 73 (33)
cART, n (%) 117 (68) 153 (69)
Co-infections, n (%)
  Hepatitis B virus infection 17 (10) 27 (12)
  Hepatitis C virus infection 15 (9) 22 (10)
  Gonorrhoea 4 (2) 5 (2)
  Chlamydia 4 (2) 6 (3)
Data are presented as n (%) unless otherwise indicated. 
MSM: men who have sex with men; IQR: interquartile range; SD: standard 
deviation; cART: combination antiretroviral therapy.
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ment for age and propensity score. The analysis was 
repeated including only individuals with one episode of 
syphilis within the study period; however, this rendered 
the same result. Among these 20 cases, 2 individuals 
contributed with more than one episode of serological 
failure. The first individual contributed with 3 episodes 
(one episode was treated with procaine penicillin, one 
episode with benzathine penicillin G and one episode 
with doxycycline). The other individual contributed with 
2 episodes and was diagnosed with relapse due to malaise 
and persisting seroreactivity one year after treatment of 
early latent syphilis. This patient had been treated with 
doxycycline for 14 days, followed by a documented 
4-fold decrease in RPR. Titres subsequently stabilized, 
but did not reverse, and the patient received retreatment 
with doxycycline for 30 days, but remained seroreactive 
thereafter. The patient was an 80-year old man with 9 
previous episodes of syphilis and re-infection could not 
be ruled out completely. In all other cases of serological 
failure the patients did not receive retreatment and no 
indications of re-infection were found. 
When comparing RPR titres between treatment groups 
at time of diagnosis and 3, 6, 9 and 12 months post-
treatment no statistically significant differences were 
observed (all p > 0.05) (Table SI1). As a consequence, 
further analyses were conducted using combined data 
from the doxycycline and penicillin groups. At the time 
of diagnosis, there was a statistically significant diffe-
rence in RPR between syphilis stages (p = 0.02). From 
the descriptive statistics it was evident that the highest 
titres were observed during the secondary stage (RPR 
128) compared with the primary stage (RPR 32), the early 
latent stage (RPR 64) and the late latent stage (RPR 64). 
Among the cases with primary and secondary syphilis, 
100% and 89% reached serological cure at 12 months, 
respectively, and of the cases with early and late latent 
syphilis it was 71% and 67%, respectively (p = 0.006). 
RPR titres at the time of diagnosis were significantly 
higher in patients with serological failure 12 months after 
treatment (p < 0.000). However, the serological cure rate 
did not vary by CD4 cell count or HIV RNA (all p > 0.05). 
Propensity-score-matched case-control study 
Seventeen patients in the doxycycline group were 
matched with the 17 patients in the penicillin group who 
had the closest propensity scores. Two patients (12%) 
in the matched doxycycline group and 3 (18%) in the 
matched penicillin group had serological failure at 12 
months (crude OR 0.62 (95% CI 0.09–4.29), p = 0.5). 
DISCUSSION
In this propensity-score-adjusted and propensity-score-
matched case-control study we assessed the serolo-
gical treatment response in 202 cases of syphilis in 
HIV-infected individuals; 127 cases were treated with 
doxycycline and 75 were treated with intramuscular 
penicillin. Current treatment guidelines in Europe 
and the USA recommend penicillin as the preferred 
treatment option, whereas doxycycline is reserved 
for patients who are allergic to penicillin (1, 2). Our 
findings suggest that doxycycline can be used as an 
efficient alternative, at least in an HIV-infected popula-
tion with close serological and clinical follow-up. In a 
recent study comparing single dose with multiple doses 
of benzathine penicillin G for treatment of syphilis in 
HIV-infected individuals, 91% of the included patients 
exhibited serological cure by 13 months and 97% by 
2 years (23). In addition, a systematic review found a 
failure rate of 1–22% among HIV-infected individuals 
(24). In our study, serological cure rates of 85% and 
83% for doxycycline and penicillin, respectively, fall 
within this range and furthermore no difference in 
serological outcome was observed between 
treatment groups. Moreover, a previous study 
from our group with the primary objective to 
assess the effect of syphilis and HIV coinfec-
tion on viral load and CD4 cell count found 
comparable response rates to treat ment with 
penicillin and doxycycline (25). 
A study by Sena et al. (26) demonstrated 
that persisting non-treponemal titres were 
common among patients with early syphilis 
and that re-treatment had only a minor effect 
Table II. Serological outcomes 3, 6, 9 and 12 months after treatment (n=202 
cases). Serological cure was defined as a ≥ 4-fold decline in rapid plasma reagin 
(RPR). Serological failure was defined as a lack of a 4-fold decline in RPR
Serological 
outcome
3 months 6 months 9 months 12 months
Doxy 
(n = 89)
PC 
(n = 58)
Doxy 
(n = 74)
PC 
(n = 45)
Doxy  
(n = 68)
PC  
(n = 39)
Doxy  
(n = 78)
PC  
(n = 48)
Cure, n (%) 20 (22) 12 (21) 37 (50) 28 (62) 52 (76) 31 (79) 66 (85) 40 (83)
Failure, n (%) 69 (78) 46 (79) 37 (50) 17 (38) 16 (24)   8 (21) 12 (15)   8 (17)
n: number of cases with available serological test results at each time-point. Doxy: 
doxycycline; PC: penicillin.
Fig. 1. Inclusion of cases for comparison of serological treatment outcomes. 
IV: intravenous; STD: sexually transmitted diseases.
Cases from 3 study sites (n=221) 
Excluded (n=19) 
Neurosyphilis (n=14) 
Treated with IV antibiotics (n=2) 
No information on therapy (n=3) 
Study site: Rigshospitalet 
Doxycycline (n=106)
Penicillin (n=7)
Study site: STD clinic 
(n=25) 
Doxycycline (n=4)
Penicillin (n=21)
Included cases (n=202) 
Study site: Hvidovre Hospital
 (n=64) 
Doxycycline (n=17)
Penicillin (n=47)
Included cases (n=202) 
Doxycycline (n=127)
Penicillin (n=75)
(n=113) 
Acta Derm Venereol 96
810 K. Salado-Rasmussen et al.
on serofast patients. In keeping with this, one patient in 
our study was diagnosed with relapse and the patient 
did not serorevert despite retreatment. Another study 
showed that patients experiencing their first infection 
were more likely to serorevert than patients with repea-
ted infection (27). A more recent large study in a HIV-
uninfected population assessed factors associated with 
serological response in patients with early syphilis and 
found that serological cure at 6 months after treatment 
was associated with younger age and fewer sex partners, 
but surprisingly not with a history of syphilis (28). Ac-
cordingly, whether persistent seroreactivity represents 
low-level infection or is caused by variability in the 
host response remains controversial.
We found a higher rate of serological cure in earlier 
stages of syphilis. The highest rates of serological cure 
at 12 months were seen in the primary and secondary 
stages. Previous studies have also reported slower se-
rological responses in late stages of syphilis (15, 27, 
29). Likewise, a study similar to ours, comparing doxy-
cycline and penicillin, corroborated that HIV-infected 
patients with secondary syphilis were more likely to 
achieve serological cure than patients in other stages 
(30). CD4 cell count has also been shown to have an 
effect on serological treatment outcome; a CD4 cell 
count of < 200 cells/µl at the time of syphilis diagnosis 
has been associated with an increased risk of serologi-
cal failure (16). Nevertheless, no such association was 
demonstrated in our study. 
The strengths of the current study include the close 
follow-up and the detailed demographic, clinical and 
behavioural data on all patients. Furthermore, to capture 
all serological data, results of serological tests were ob-
tained from the national provider of serological syphilis 
testing. The samples were not batched, but all analyses 
were performed at the same laboratory. All reactive 
non-treponemal tests were confirmed using treponemal 
tests, thereby minimizing the risk of false-positive test 
results. Of note, the use of cART appears to decrease 
the prevalence of biologic false-positive tests in HIV-
infected individuals (31). Also, all patient files were 
reviewed, enabling us to confirm that seroreactive tests 
were clinically perceived as a case and to distinguish 
between relapse and re-infection. Finally, in contrast 
to others, our study also included patients with late 
latent-stage syphilis. 
This study is limited by the retrospective non-
randomized design. The treatment given was based 
on local guidelines and the patients at the Department 
of Infectious Diseases at Rigshospitalet were mainly 
treated with doxycycline, whereas patients at the De-
partment of Infectious Diseases at Hvidovre Hospital 
and the STD clinic at Bispebjerg Hospital were mainly 
treated with penicillin. However, the patients in the 2 
treatment groups were comparable, except for the pro-
portion on cART and the CD4 cell count. The patients in 
this study were all attending either of the 2 departments 
of infectious diseases for treatment or monitoring of 
their HIV infection; however, for treatment of syphilis, 
some of these patients opted for the STD clinic. More 
HIV-infected individuals not receiving cART opted for 
treatment at the STD clinic compared with individuals 
on cART. This explains the lower proportion of patients 
on cART in the group receiving penicillin (the preferred 
regimen at the STD clinic). Likewise, even though the 
median CD4 cell count was comparable between treat-
ment groups, a higher proportion of patients with CD4 
cell counts ≤ 200 cells/µl were treated with penicillin. 
The similar response rates in the treatment groups might 
be caused by the higher proportion of patients with low 
CD4 cell counts in the penicillin group because low CD4 
cell counts have been associated with increased risk of 
treatment failure and delayed treatment response in HIV-
infected individuals (32). Confounding by indication, i.e. 
that physicians may tend to use intramuscular penicillin 
for patients who are more severely ill and less compliant, 
is a risk when doing a retrospective study of treatment 
options, but our treatment groups were comparable 
overall. Using propensity scores to adjust for a skewed 
use of doxycycline and penicillin can reduce this bias by 
balancing covariates in the different treatment groups. 
In our study the results were largely unchanged after 
adjusting for the propensity score. The propensity score-
matched study was small, but the OR was nevertheless 
very comparable to the propensity score adjusted OR. 
Also, because benzathine penicillin G does not achieve 
treponemicidal levels in the cerebrospinal fluid (CSF) 
and doxycycline conversely penetrates into the CSF 
(1), patients with asymptomatic neurosyphilis may have 
benefitted from treatment with doxycycline, resulting in 
an increased risk of treatment failure in the penicillin 
group. Finally, the vast majority of the patients in this 
study were MSM and whether our results are generali-
zable to other populations is unknown. 
Systematic reviews have concluded that guidelines 
for treatment of HIV-infected individuals are based on 
very few objective data (24, 33). Whether doxycycline 
is equipotent to penicillin can only be evaluated defini-
tively in a randomized clinical trial. However, with the 
well-functioning treatments with penicillin such a study 
might not counteract the costs of a large clinical trial. 
Regardless of its observational design, our study provi-
des evidence for the use of doxycycline as an acceptable 
treatment option for patients with close follow-up, who 
prefer oral treatment for syphilis. A study similar to ours, 
comparing doxycycline and penicillin in HIV-infected 
individuals supports this assumption (30), although 
their response rates to both penicillin and doxycycline 
were lower than in our study and lower than previously 
reported (6). In addition, doxycycline is an effective 
agent for treatment of multiple STDs (33). Importantly, 
all our patients had concurrent HIV, but the results may 
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be generalizable to patients without HIV although the 
requirement of multiple days of treatment may present 
a problem in a population less used to daily medication. 
Taken together, our study supports the use of doxycycline 
as an efficient treatment option for syphilis when treating 
an HIV-infected population with close follow-up.
The authors declare no conflicts of interest
REFERENCES
1. Janier M, Hegyi V, Unemo M, Tiplica GS, Potocnik M, 
French P, et al. 2014 European guideline on the management 
of syphilis. IUSTI 2014.
2. MMWR. Sexually transmitted diseases treatment guidelines. 
Centers for Disease Control and Prevention, U.S. Department 
of Health and Human Services, Atlanta; 2010.
3. Hendricks FD, Greaves AB, Olansky S, Taggart SR, Lewis 
CN, Landman GS, et al. Terramycin in the treatment of 
venereal disease; a preliminary report. J Am Med Assoc 
1950; 143: 4–5.
4. Kierland RR, Herrell WE, O’Leary PA. Treatment of sy-
philis with aureomycin administered by mouth. Arch Derm 
Syphilol 1950; 61: 185–195.
5. Onoda Y. Therapeutic effect of oral doxycycline on syphilis. 
Br J Vener Dis 1979; 55: 110–115.
6. Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM. 
Doxycycline compared with benzathine penicillin for the tre-
atment of early syphilis. Clin Infect Dis 2006; 42: e45–e49.
7. Lukehart SA, Godornes C, Molini BJ, Sonnett P, Hopkins 
S, Mulcahy F, et al. Macrolide resistance in Treponema 
pallidum in the United States and Ireland. N Engl J Med 
2004; 351: 154–158.
8. Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes 
C, Klausner JD. Azithromycin-resistant syphilis infection: 
San Francisco, California, 2000–2004. Clin Infect Dis 
2006; 42: 337–345.
9. Martin IE, Gu W, Yang Y, Tsang RS. Macrolide resistance 
and molecular types of Treponema pallidum causing pri-
mary syphilis in Shanghai, China. Clin Infect Dis 2009; 
49: 515–521.
10. Tipple C, Taylor GP. Syphilis testing, typing, and treatment 
follow-up: a new era for an old disease. Curr Opin Infect 
Dis 2015; 28: 53–60.
11. Salado-Rasmussen K, Katzenstein TL, Gerstoft J, Cowan 
SA, Knudsen TB, Mathiesen L, et al. Risk of HIV or se-
cond syphilis infection in Danish men with newly acquired 
syphilis in the period 2000–2010. Sex Transm Infect 2013; 
89: 372–376.
12. Berry CD, Hooton TM, Collier AC, Lukehart SA. Neurolo-
gic relapse after benzathine penicillin therapy for secondary 
syphilis in a patient with HIV infection. N Engl J Med 
1987; 316: 1587–1589.
13. Zetola NM, Klausner JD. Syphilis and HIV infection: an 
update. Clin Infect Dis 2007; 44: 1222–1228.
14. Rolfs RT, Joesoef MR, Hendershot EF, Rompalo AM, Au-
genbraun MH, Chiu M, et al. A randomized trial of enhan-
ced therapy for early syphilis in patients with and without 
human immunodeficiency virus infection. The Syphilis 
and HIV Study Group. N Engl J Med 1997; 337: 307–314.
15. Knaute DF, Graf N, Lautenschlager S, Weber R, Bosshard 
PP. Serological response to treatment of syphilis according 
to disease stage and HIV status. Clin Infect Dis 2012; 55: 
1615–1622.
16. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Ze-
nilman JM, Gebo KA. Antiretroviral therapy is associated 
with reduced serologic failure rates for syphilis among 
HIV-infected patients. Clin Infect Dis 2008; 47: 258–265.
17. Brown ST, Zaidi A, Larsen SA, Reynolds GH. Serological 
response to syphilis treatment. A new analysis of old data. 
JAMA 1985; 253: 1296–1299.
18. Rubin DB, Thomas N. Matching using estimated propen-
sity scores: relating theory to practice. Biometrics 1996; 
52: 249–264.
19. D’Agostino RB, Jr. Propensity score methods for bias 
reduction in the comparison of a treatment to a non-
randomized control group. Stat Med 1998; 17: 2265–2281.
20. Pedersen NS, Petersen CS, Axelsen NH. Enzyme-linked 
immunosorbent assay for detection of immunoglobulin M 
antibody against the Reiter treponeme flagellum in syphilis. 
J Clin Microbiol 1982; 16: 608–614.
21. Pedersen NS, Sheller JP, Ratnam AV, Hira SK. Enzyme-
linked immunosorbent assays for detection of immunoglo-
bulin M to nontreponemal and treponemal antigens for the 
diagnosis of congenital syphilis. J Clin Microbiol 1989; 
27: 1835–1840.
22. Pedersen NS, Petersen CS, Vejtorp M, Axelsen NH. Sero-
diagnosis of syphilis by an enzyme-linked immunosorbent 
assay for IgG antibodies against the Reiter treponeme 
flagellum. Scand J Immunol 1982; 15: 341–348.
23. Ganesan A, Mesner O, Okulicz JF, O’Bryan T, Deiss RG, 
Lalani T, et al. A single dose of Benzathine Penicillin G is 
as effective as multiple doses of benzathine penicillin G for 
the treatment of HIV-infected persons with early syphilis. 
Clin Infect Dis 2015; 60: 653–660.
24. Blank LJ, Rompalo AM, Erbelding EJ, Zenilman JM, Gha-
nem KG. Treatment of syphilis in HIV-infected subjects: 
a systematic review of the literature. Sex Transm Infect 
2011; 87: 9–16.
25. Kofoed K, Gerstoft J, Mathiesen LR, Benfield T. Syphilis 
and human immunodeficiency virus (HIV)-1 coinfection: 
influence on CD4 T-cell count, HIV-1 viral load, and treat-
ment response. Sex Transm Dis 2006; 33: 143–148.
26. Sena AC, Wolff M, Behets F, Van DK, Martin DH, Leone 
P, et al. Response to therapy following retreatment of sero-
fast early syphilis patients with benzathine penicillin. Clin 
Infect Dis 2013; 56: 420–422.
27. Romanowski B, Sutherland R, Fick GH, Mooney D, Love 
EJ. Serologic response to treatment of infectious syphilis. 
Ann Intern Med 1991; 114: 1005–1009.
28. Sena AC, Wolff M, Martin DH, Behets F, Van DK, Leone P, 
et al. Predictors of serological cure and serofast state after 
treatment in HIV-negative persons with early syphilis. Clin 
Infect Dis 2011; 53: 1092–1099.
29. Ghanem KG, Erbelding EJ, Wiener ZS, Rompalo AM. 
Serological response to syphilis treatment in HIV-positive 
and HIV-negative patients attending sexually transmitted 
diseases clinics. Sex Transm Infect 2007; 83: 97–101.
30. Tsai JC, Lin YH, Lu PL, Shen NJ, Yang CJ, Lee NY, et al. 
Comparison of serological response to doxycycline versus 
benzathine penicillin G in the treatment of early syphilis in 
HIV-infected patients: a multi-center observational study. 
PLoS ONE 2014; 9: e109813.
31. Oboho IK, Gebo KA, Moore RD, Ghanem KG. The impact 
of combined antiretroviral therapy on biologic false-positive 
rapid plasma reagin serologies in a longitudinal cohort of 
HIV-infected persons. Clin Infect Dis 2013; 57: 1197–1202.
32. Jinno S, Anker B, Kaur P, Bristow CC, Klausner JD. Pre-
dictors of serological failure after treatment in HIV-infected 
patients with early syphilis in the emerging era of universal 
antiretroviral therapy use. BMC Infect Dis 2013; 13: 605.
33. Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: 
a systematic review. JAMA 2014; 312: 1905–1917.
Acta Derm Venereol 96
